Themis Medicare Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹90Cr
- −3.9% YoY
- +15.6% QoQ
- Net profit
- ₹10Cr
- +1840.4% YoY
- Turned profitable QoQ
- Margin
- 10.87%
- +4.5 pp YoY
- +14.8 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Themis Medicare Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY26 net revenue: Rs. 90.13 Cr, a 3.9% decline year-on-year from Rs. 93.81 Cr in Q3 FY25 (Page 8). Q3 FY26 Financials (Page 8 & 7):.
From Themis Medicare Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY26 net revenue: Rs. 90.13 Cr, a 3.9% decline year-on-year from Rs. 93.81 Cr in Q3 FY25 (Page 8).
- 9M FY26 net revenue: Rs. 265.71 Cr, a 20.4% decline year-on-year from Rs. 333.81 Cr in 9M FY25 (Page 9).
- Q3 FY26: API business grew more than double YoY, partially offset by softness in formulations segment (Page 5).
2 more points from Themis Medicare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Page 14 lists current manufacturing facilities and their capacities:
- Haridwar: Formulations (520 mn Tablets, 9 mn Ointment Tubes, 36 mn Ampoules, 12 mn Vials, 6 mn Pre-filled Syringes)
- Hyderabad and Vapi: Synthetic APIs with capacities of 120 MT and 191 MT respectively.
- Page 15 mentions continued R&D investment (~Rs. 13-14 Cr annually) but no direct capex or expansion timelines.
- Page 18 hints at strategic expansion plans:
- Phase I (0-3 years): Focus on new Rest of World markets (CIS, Latin America, GCC)
2 more points from Themis Medicare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Themis Medicare Ltd said on order book & pipeline — free account, 30 seconds.
Themis Medicare Ltd — Quarterly revenue & net profit
Themis Medicare Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 90 | 94 | -3.9% | 78 | +15.6% |
| Operating profit (EBITDA) | 10 | 6 | +64.2% | -3 | — |
| Operating margin | 10.87% | 6.36% | +4.5 pp | -3.97% | +14.8 pp |
| Profit before tax | 10 | 2 | +525.9% | -3 | — |
| Net profit (PAT) | 10 | 1 | +1840.4% | -4 | — |
| EPS (₹) | 1.10 | 0.06 | +1733.3% | -0.39 | — |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹90 Cr, net profit ₹7 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Themis Medicare Ltd Q3 FY26 results?
Q3 FY26 net revenue: Rs. 90.13 Cr, a 3.9% decline year-on-year from Rs. 93.81 Cr in Q3 FY25 (Page 8). Q3 FY26 Financials (Page 8 & 7):.
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
